Adam Koprowski is the General Director of K2 Biomedical. He is well experienced manager, especially in the field of innovative projects conducted in Health Care. He was working in the scientific and research projects in few institution : Pope John Paul II Hospital in Krakow (1993-2002), Cracow Center for Telemedicine and Preventive Medicine (1999-2002), Institute of Cardiology (Warsaw, 2002-2007) cooperating closely with prof. Zbigniew Religa. In the Institute of Cardiology he was responsible for projects in the field of Telemedicine and implementation of modern mobile telemonitoring systems. Deputy Director in the National Centre for Health Information Systems (2007-2010) where he coordinate projects at regional and national level regarding health data.
Operational Programme Smart Growth 2014-2020
Project title: Development of a new candidate microbicide for the prevention of HIV transmission
Application no.: POIR.01.02.00-00-0003/17
On December 2017 r. K2Biomedical signed a contract with the National Centre for Research and Development for co-financing a research project, which aims to develop an innovative microbicide used in the prevention of sexually transmitted infections, in particular in the prevention of HIV virus and potentially HPV virus causing cervical cancer and HSV-2 virus.
A product innovation that will be created within the Project - a new candidate for a microbicide – eventually will be in the form of a topically applied gel protecting the user from being infected by the aforementioned viruses. The new product is also anticipated to feature contraceptive and lubricating action. Factors determining the demand for the product are derived directly from the current state of knowledge on prevention of STI and the preventive measures currently offered on the market. Owing to its unique formula, the product will be characterized by a number of features and functionalities that distinguish it from previous microbicide candidates. The target product profile (TPP) for the NOV-1003 gel includes following features: on demand use that does not require daily dosing; broad activity against viral and bacterial STIs including HIV infection; dual compartment protection; woman-controlled contraception; over the counter (OTC) availability.
The Project will consist of two work packages. WP1 (industrial research) will be dedicated to GLP compliant IND enabling studies as final preclinical development. WP2’s (expermintal development) aim will be to conduct I Phase of clinical trials in accordance with trial protocol and production of the final report, which due to definition of NOV-1003 safety profile will be used for decision about clinical trials continuation.
Project co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2:
Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020.
Total amount: 9,928,239.50 PLN
Co-funding amount: 7,034,900.75 PLN
Project Tender_Experimental Preclinical Studies
Project Tender - Drug Substance Production
Project Tender - GLP Tox Bioavailability
Project Tender - Regulatory
Project Tender - Microbicide Gel GMP Production
IN VIVO TOXICOLOGY request for NOV1004
REGULATORY SERVICES request for NOV1004
STABILITY STUDY request for NOV1004